Teleflex (NYSE:TFX) Announces Earnings Results

Teleflex (NYSE:TFX) announced its quarterly earnings data on Thursday. The medical technology company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.18, Briefing.com reports. The business had revenue of $548.30 million for the quarter, compared to analysts’ expectations of $536.91 million. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The business’s revenue was up 32.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.44 earnings per share. Teleflex updated its FY 2026 guidance to 6.250-6.550 EPS.

Here are the key takeaways from Teleflex’s conference call:

• Teleflex says its strategic divestitures remain on track to close in H2 2026 (OEM HSR period expired and OEM expected to close in Q3), and it intends to use roughly $1.8 billion of net proceeds to fund up to a $1 billion share repurchase program and repay about $800 million of debt, with opportunistic buybacks to begin in Q2.
• First quarter continuing-operations revenue was $548.3M (GAAP +32.3%, pro forma adjusted constant currency +5.1%) while adjusted EPS was $1.39 (down 3.5% YoY), with adjusted operating margin at 18.1% reflecting near-term margin pressure from tariffs, logistics, the vascular intervention acquisition and remediation charges.
• Management disclosed two third?party supplier recalls affecting components in some vascular interventional kits, has taken remediation provisions in Q1, and warns the recalls may cause elevated backorders in Q2 even though they do not currently expect a material full?year revenue impact.
• 2026 guidance remains pro forma revenue growth of 4.5%–5.5% and adjusted EPS of $6.25–$6.55, but assumes about $90 million of stranded costs and a fully burdened operating margin near 19% (management estimates a ~23% steady?state margin once TSAs/MSAs and separation impacts are realized, with meaningful EPS improvement expected in 2027).
• R&D momentum: the Freesolve drug?eluting resorbable magnesium scaffold program (BIOMAG?II) is enrolling ahead of plan with a late?2027 EU readout expected and a U.S. pivotal (BIOMAG?III) planned to start in 2026, representing a potential long?term growth driver.

Teleflex Stock Up 1.1%

Shares of NYSE:TFX traded up $1.49 during trading on Friday, reaching $133.17. 947,217 shares of the stock traded hands, compared to its average volume of 1,030,809. The stock has a 50-day moving average of $119.44 and a two-hundred day moving average of $116.73. Teleflex has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.01 and a current ratio of 2.55. The stock has a market cap of $5.89 billion, a P/E ratio of -5.84, a price-to-earnings-growth ratio of 0.96 and a beta of 0.82.

Teleflex Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were issued a dividend of $0.34 per share. The ex-dividend date was Friday, March 6th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.0%. Teleflex’s dividend payout ratio is presently -5.96%.

Teleflex News Summary

Here are the key news stories impacting Teleflex this week:

• Positive Sentiment: Teleflex beat Q1 estimates, reporting adjusted EPS of $1.39 versus $1.21 expected and revenue of $548.3 million versus $536.9 million expected, which signals solid execution in the quarter. Article Title
• Positive Sentiment: The company maintained its full-year 2026 outlook and announced plans for a buyback, which can support investor confidence and share price performance. Article Title
• Positive Sentiment: Wells Fargo raised its price target on TFX from $130 to $138, implying modest upside from current levels and suggesting improved analyst sentiment. Article Title
• Neutral Sentiment: Management’s earnings call commentary was described as balanced, with growth offset by margin strain, indicating the business is still navigating profitability pressure even after the earnings beat. Article Title
• Negative Sentiment: Teleflex’s updated FY2026 EPS guidance of $6.25 to $6.55 came in below the market’s expectation of about $6.73, which could limit enthusiasm despite the quarterly beat. Article Title

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Wall Street Zen cut shares of Teleflex from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Research upgraded shares of Teleflex from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 28th. Wells Fargo & Company upped their price objective on shares of Teleflex from $130.00 to $138.00 and gave the stock an “equal weight” rating in a report on Friday. Raymond James Financial restated an “outperform” rating and issued a $150.00 price objective on shares of Teleflex in a report on Friday. Finally, Bank of America upgraded shares of Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective on the stock in a report on Monday, April 13th. Three analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $142.86.

Institutional Investors Weigh In On Teleflex

Institutional investors have recently made changes to their positions in the company. Coldstream Capital Management Inc. bought a new position in Teleflex during the third quarter valued at approximately $215,000. Advisory Services Network LLC bought a new position in Teleflex during the third quarter valued at approximately $142,000. Northwestern Mutual Wealth Management Co. lifted its position in Teleflex by 213.5% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 1,759 shares of the medical technology company’s stock valued at $215,000 after purchasing an additional 1,198 shares during the period. Perbak Capital Partners LLP bought a new position in Teleflex during the third quarter valued at approximately $205,000. Finally, Quadrant Capital Group LLC bought a new position in Teleflex during the third quarter valued at approximately $166,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.